SCHEMBL4893382

SCHEMBL4893382

CCOC(=O)C1CCN(CC(=O)Nc2ccc(C)c(Nc3nccc(-c4ccccn4)n3)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
KDM4E B2RXH2 3/20 0.50
PTK2 Q05397 1/20 0.49
TP53 P04637 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ABL1 P00519 6/20 0.48
KIT P10721 2/20 0.48
ABL2 P42684 1/20 0.48
ABCB1 P08183 2/20 0.47
DRD2 P14416 2/20 0.46
DRD4 P21917 2/20 0.46
DRD3 P35462 2/20 0.46
BCR P11274 4/20 0.45
PDGFRB P09619 2/20 0.45
EGFR P00533 1/20 0.45
PDGFRA P16234 1/20 0.45
PRKCA P17252 1/20 0.45
SYK P43405 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903752 0.90 PTK2 (0.56) LMNAKDM4EPTK2TP53SMN1; SMN2
SCHEMBL4900317 0.90 DRD2 (0.51) LMNAKDM4EPTK2TP53SMN1; SMN2
SCHEMBL4892565 0.88 ABL1 (0.54) LMNAKDM4EPTK2TP53SMN1; SMN2
SCHEMBL4903273 0.88 ALDH1A1 (0.54) LMNAKDM4ESMN1; SMN2ABL1KIT
SCHEMBL4904891 0.88 ABL1 (0.61) LMNAABL1KITABL2ABCB1
SCHEMBL4892505 0.85 ABL1 (0.57) LMNAABL1KITABL2ABCB1
SCHEMBL4896431 0.85 ABL1 (0.52) ABL1KITABL2ABCB1BCR
SCHEMBL4901214 0.79 PDGFRA (0.64) ABL1KITABL2BCRPDGFRB
SCHEMBL4900835 0.79 LMNA (0.50) LMNAKDM4EPTK2SMN1; SMN2ABL1
SCHEMBL4903667 0.78 PTK2 (0.53) LMNAKDM4EPTK2SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP LMNA 1955/4885KDM4E 2352/4885PTK2 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.